Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 212

1.

Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.

Lam SW, Nota NM, Jager A, Bos MM, van den Bosch J, van der Velden AM, Portielje JE, Honkoop AH, van Tinteren H, Boven E; ATX trial team.

Clin Cancer Res. 2016 Apr 1;22(7):1611-20. doi: 10.1158/1078-0432.CCR-15-1005. Epub 2016 Jan 28.

PMID:
26823602
2.

Sunitinib-induced hypertension in CYP3A4 rs4646437 A-allele carriers with metastatic renal cell carcinoma.

Diekstra MH, Belaustegui A, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, García-Donas J, Rodríguez-Antona C, Rini BI, Guchelaar HJ.

Pharmacogenomics J. 2016 Jan 26. doi: 10.1038/tpj.2015.100. [Epub ahead of print]

PMID:
26810136
3.

Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.

Frederiks CN, Lam SW, Guchelaar HJ, Boven E.

Cancer Treat Rev. 2015 Dec;41(10):935-50. doi: 10.1016/j.ctrv.2015.10.010. Epub 2015 Oct 30. Review.

PMID:
26585358
4.

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.

Diekstra MH, Liu X, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, Rini BI, Guchelaar HJ.

Eur J Clin Pharmacol. 2015 Dec;71(12):1477-84. doi: 10.1007/s00228-015-1935-7. Epub 2015 Sep 21.

5.

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, Rini BI, Guchelaar HJ.

Eur Urol. 2015 Oct;68(4):621-9. doi: 10.1016/j.eururo.2015.04.018. Epub 2015 Apr 27.

PMID:
25930089
6.

Effect of Low-Intensity Physical Activity and Moderate- to High-Intensity Physical Exercise During Adjuvant Chemotherapy on Physical Fitness, Fatigue, and Chemotherapy Completion Rates: Results of the PACES Randomized Clinical Trial.

van Waart H, Stuiver MM, van Harten WH, Geleijn E, Kieffer JM, Buffart LM, de Maaker-Berkhof M, Boven E, Schrama J, Geenen MM, Meerum Terwogt JM, van Bochove A, Lustig V, van den Heiligenberg SM, Smorenburg CH, Hellendoorn-van Vreeswijk JA, Sonke GS, Aaronson NK.

J Clin Oncol. 2015 Jun 10;33(17):1918-27. doi: 10.1200/JCO.2014.59.1081. Epub 2015 Apr 27.

7.

Adherence, exposure and patients' experiences with the use of erlotinib in non-small cell lung cancer.

Timmers L, Boons CC, Moes-Ten Hove J, Smit EF, van de Ven PM, Aerts JG, Swart EL, Boven E, Hugtenburg JG.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1481-91. doi: 10.1007/s00432-015-1935-0. Epub 2015 Mar 6.

8.

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

Lam SW, de Groot SM, Honkoop AH, Jager A, ten Tije AJ, Bos MM, Linn SC, van den Bosch J, Kroep JR, Braun JJ, van Tinteren H, Boven E; Dutch Breast Cancer Research Group.

Eur J Cancer. 2014 Dec;50(18):3077-88.

PMID:
25459393
9.

Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling.

de Wit M, Kant H, Piersma SR, Pham TV, Mongera S, van Berkel MP, Boven E, Pontén F, Meijer GA, Jimenez CR, Fijneman RJ.

J Proteomics. 2014 Mar 17;99:26-39. doi: 10.1016/j.jprot.2014.01.001. Epub 2014 Jan 10.

PMID:
24418523
10.

Adherence and patients' experiences with the use of oral anticancer agents.

Timmers L, Boons CC, Kropff F, van de Ven PM, Swart EL, Smit EF, Zweegman S, Kroep JR, Timmer-Bonte JN, Boven E, Hugtenburg JG.

Acta Oncol. 2014 Feb;53(2):259-67. doi: 10.3109/0284186X.2013.844353. Epub 2013 Nov 22.

PMID:
24266637
11.

Breast cancer classification by proteomic technologies: current state of knowledge.

Lam SW, Jimenez CR, Boven E.

Cancer Treat Rev. 2014 Feb;40(1):129-38. doi: 10.1016/j.ctrv.2013.06.006. Epub 2013 Jul 23. Review.

PMID:
23891266
12.

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance.

Warmoes M, Jaspers JE, Xu G, Sampadi BK, Pham TV, Knol JC, Piersma SR, Boven E, Jonkers J, Rottenberg S, Jimenez CR.

Mol Cell Proteomics. 2013 May;12(5):1319-34. doi: 10.1074/mcp.M112.024182. Epub 2013 Feb 8.

13.

Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study.

Hamaker ME, Seynaeve C, Nortier JW, Wymenga M, Maartense E, Boven E, van Leeuwen-Stok AE, de Rooij SE, van Munster BC, Smorenburg CH.

Breast. 2013 Aug;22(4):556-9. doi: 10.1016/j.breast.2012.12.010. Epub 2013 Jan 8.

PMID:
23305962
14.

The use of capecitabine in daily practice: a study on adherence and patients' experiences.

Timmers L, Swart EL, Boons CC, Mangnus D, van de Ven PM, Peters GJ, Boven E, Hugtenburg JG.

Patient Prefer Adherence. 2012;6:741-8. doi: 10.2147/PPA.S36757. Epub 2012 Oct 19.

15.

Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial.

Duijts SF, van Beurden M, Oldenburg HS, Hunter MS, Kieffer JM, Stuiver MM, Gerritsma MA, Menke-Pluymers MB, Plaisier PW, Rijna H, Lopes Cardozo AM, Timmers G, van der Meij S, van der Veen H, Bijker N, de Widt-Levert LM, Geenen MM, Heuff G, van Dulken EJ, Boven E, Aaronson NK.

J Clin Oncol. 2012 Nov 20;30(33):4124-33. doi: 10.1200/JCO.2012.41.8525. Epub 2012 Oct 8.

16.

Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.

Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E.

Clin Pharmacol Ther. 2012 Oct;92(4):503-10. doi: 10.1038/clpt.2012.136. Epub 2012 Sep 5.

PMID:
22948895
17.

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours.

Kaye S, Aamdal S, Jones R, Freyer G, Pujade-Lauraine E, de Vries EG, Barriuso J, Sandhu S, Tan DS, Hartog V, Kuenen B, Ruijter R, Kristensen GB, Nyakas M, Barrett S, Burke W, Pietersma D, Stuart M, Emeribe U, Boven E.

Br J Cancer. 2012 May 22;106(11):1728-34. doi: 10.1038/bjc.2012.158. Epub 2012 Apr 24.

18.

SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation.

Ruiterkamp J, Voogd AC, Tjan-Heijnen VC, Bosscha K, van der Linden YM, Rutgers EJ, Boven E, van der Sangen MJ, Ernst MF; Dutch Breast Cancer Trialists' Group (BOOG).

BMC Surg. 2012 Apr 2;12:5. doi: 10.1186/1471-2482-12-5.

19.

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer.

Warmoes M, Jaspers JE, Pham TV, Piersma SR, Oudgenoeg G, Massink MP, Waisfisz Q, Rottenberg S, Boven E, Jonkers J, Jimenez CR.

Mol Cell Proteomics. 2012 Jul;11(7):M111.013334. doi: 10.1074/mcp.M111.013334. Epub 2012 Feb 24.

20.

Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.

Vermaat JS, Gerritse FL, van der Veldt AA, Roessingh WM, Niers TM, Oosting SF, Sleijfer S, Roodhart JM, Beijnen JH, Schellens JH, Gietema JA, Boven E, Richel DJ, Haanen JB, Voest EE.

Eur Urol. 2012 Oct;62(4):685-95. doi: 10.1016/j.eururo.2012.01.020. Epub 2012 Jan 23.

PMID:
22285764
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk